ATXI (Avenue Therapeutics) Cyclically Adjusted Book per Share: $439.84 (As of Mar. 2026)


ATXI Avenue Therapeutics Inc ATXI
31 GF Score
Price $0.31
! 1 Warning Sign
View Full Analysis

What is Avenue Therapeutics Cyclically Adjusted Book per Share?

Avenue Therapeutics ATXI +8.93% 31 Cyclically Adjusted Book per Share is $439.84 as of Mar. 2026. GuruFocus rates ATXI with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Avenue Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was $0.364. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $439.84 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-03), Avenue Therapeutics's current stock price is $0.305. Avenue Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $439.84. Avenue Therapeutics's Cyclically Adjusted PB Ratio of today is 0.00.


Avenue Therapeutics  (OTCPK:ATXI) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Avenue Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.305/439.84
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Avenue Therapeutics Cyclically Adjusted Book per Share Related Terms


Avenue Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Avenue Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avenue Therapeutics Cyclically Adjusted Book per Share Chart

Avenue Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 443.30

Avenue Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 423.12 443.30 439.84

ATXI vs AGTX, CLSDQ, BZYR: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Avenue Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avenue Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avenue Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Avenue Therapeutics's Cyclically Adjusted PB Ratio falls into.


ATXI
31GF Score
Avenue Therapeutics Inc ATXI
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avenue Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Avenue Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.364/330.2130*330.2130
=0.364

Current CPI (Mar. 2026) = 330.2130.

Avenue Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 -916.444 241.432 -1,253.445
201703 -989.333 243.801 -1,339.989
201706 3,017.333 244.955 4,067.533
201709 2,687.333 246.819 3,595.316
201712 2,153.333 246.524 2,884.338
201803 1,039.222 249.554 1,375.112
201806 557.444 251.989 730.489
201809 310.444 252.439 406.089
201812 -70.111 251.233 -92.152
201903 1,356.733 254.202 1,762.421
201906 926.933 256.143 1,194.978
201909 797.400 256.759 1,025.521
201912 453.333 256.974 582.535
202003 384.867 258.115 492.370
202006 273.400 257.797 350.199
202009 215.600 260.280 273.528
202012 157.267 260.474 199.373
202103 98.333 264.877 122.588
202106 42.800 271.696 52.018
202109 -10.667 274.310 -12.841
202112 181.632 278.802 215.125
202203 57.950 287.504 66.559
202206 29.900 296.311 33.321
202209 -1.950 296.808 -2.169
202212 61.016 296.797 67.886
202303 -15.956 301.836 -17.456
202306 -50.340 305.109 -54.482
202309 -30.417 307.789 -32.633
202312 4.639 306.746 4.994
202403 4.807 312.332 5.082
202406 4.003 314.175 4.207
202409 1.627 315.301 1.704
202412 1.326 315.605 1.387
202503 1.102 319.799 1.138
202506 1.274 322.561 1.304
202509 1.117 324.800 1.136
202512 0.575 324.054 0.586
202603 0.364 330.213 0.364

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $439.84 mean?
Avenue Therapeutics (ATXI) has a Cyclically Adjusted Book per Share of $439.84 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Avenue Therapeutics and its competitors.
Is Avenue Therapeutics' Cyclically Adjusted Book per Share too high?
Avenue Therapeutics' current Cyclically Adjusted Book per Share is $439.84. Overall, Avenue Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Avenue Therapeutics' Cyclically Adjusted Book per Share compare to AGTX and CLSDQ?
Avenue Therapeutics' Cyclically Adjusted Book per Share of $439.84 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Avenue Therapeutics and its competitors. Avenue Therapeutics's current Cyclically Adjusted Book per Share is $439.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avenue Therapeutics stock overvalued right now?
Avenue Therapeutics (ATXI) has a current Cyclically Adjusted Book per Share of $439.84. The current Cyclically Adjusted Book per Share is $439.84. Avenue Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Avenue Therapeutics (ATXI), the current Cyclically Adjusted Book per Share is $439.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avenue Therapeutics Business Description

Address 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL, USA, 33154
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It is focused on advancing impactful therapies with the potential to overcome limitations of existing treatment options and ultimately transform patient outcomes. Current product candidates include ATX-04, a selective beta adrenergic agonist for Pompe disease, intravenous tramadol (IV tramadol), a Schedule IV opioid for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. The company operates in one reportable segment, the development and commercialization of therapies for the treatment of neurologic diseases.
31GF Score

Get the complete analysis for ATXI

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.31
Price